Precipitated withdrawal and buprenorphine start

A young man arrives at the emergency department asking to start treatment. He is anxious, says he is "starting to feel bad" and reports that he last used the night before. The team, excited about the opportunity, offers the first dose of buprenorphine. Half an hour later, he is sweating, vomiting, with pain all over his body and furious: "you made me worse". The team did not make a mistake in offering treatment. It made a mistake in reading the physiological moment.

NEXO is a daily medical diagnosis game: one clinical case a day, up to six progressive clues, and ICD-10 proximity feedback across five levels.

This text treats precipitated withdrawal as a problem of physiological reasoning. The idea is to understand why it happens, linking receptor pharmacology to symptom, and which clinical clues indicate whether the moment is suitable or not. Doses and starting schedules are left to your service's guideline. The choice between buprenorphine and methadone is the subject of another post in the series, on shared decision-making; here the medication has already been chosen, and the question is when and how to start without precipitating withdrawal.

Key points

• Buprenorphine has high affinity and low intrinsic activity at the mu receptor: it displaces full agonists and delivers less effect than they do.
• When there is a lot of full agonist occupying receptors, this swap produces an abrupt drop in effect, felt as intense and sudden withdrawal.
• The most useful sign for the moment of starting is objective withdrawal already present, measured with a scale, and not the time since the last use alone.
• With fentanyl, the time since the last use is misleading, because the drug accumulates and leaves the body slowly.
• Precipitated withdrawal is a clinical event to recognize and treat, and not a reason to end treatment.
• Explaining the mechanism to the person before the first dose changes the experience and the trust.

Why precipitated withdrawal is a problem of physiology

Precipitated withdrawal is not an allergic reaction nor an unpredictable side effect. It is the logical consequence of an interaction between two molecules and a receptor. Anyone who understands this interaction can predict when the risk is greater and explain to the person what is happening.

The post on how to link mechanism and symptom shows why connecting the basic cycle to the clinic improves the decision. Precipitated withdrawal is one of the clearest examples of this connection: receptor pharmacology that becomes a symptom in minutes, before your eyes.

The most common mistake

The most common mistake is treating the start as a matter of the clock: "it has been so many hours since he used, so it is fine". The clock is an approximation. What really matters is how much full agonist still occupies the receptors, and that depends on the substance, the pattern of use and the body. A case series in the emergency department described precipitated withdrawal even in people who received buprenorphine following current guidance (Spadaro et al., 2023).

The mu receptor: affinity, intrinsic activity and ceiling effect

Two pharmacology concepts explain almost everything: affinity and intrinsic activity.

Affinity

Affinity is the strength with which the molecule binds to the receptor. Buprenorphine has very high affinity for the mu receptor, higher than that of many commonly used opioids. In practice, when it arrives, it displaces whatever is occupying the receptor and stays bound for a long time. Imaging studies showed that mu receptor occupancy by buprenorphine depends on the dose and relates to suppression of withdrawal symptoms (Greenwald et al., 2014).

Intrinsic activity

Intrinsic activity is how much effect the molecule produces once bound. Buprenorphine is a partial agonist: it activates the receptor, but less than a full agonist such as heroin, morphine or fentanyl. This creates the ceiling effect, in which increasing the dose above a certain point stops increasing respiratory depression (Walsh et al., 1994).

The combination that explains the phenomenon

Combine the two concepts. A molecule that binds more strongly and activates less will replace a full agonist with a partial agonist. If the receptor was heavily stimulated, the result is a sharp drop in stimulation. The body, adapted to the full agonist, perceives that drop as intense and sudden withdrawal. A neuropharmacological model published to guide initiation in the emergency department describes exactly this logic and how it guides the choice of timing (Greenwald et al., 2022).

An analogy to explain it to the person

Analogies help when the mechanism has to fit into a short conversation. One that works well: imagine that the receptors are chairs and that the opioid the person uses is sitting in almost all of them, producing maximum effect. Buprenorphine is someone who arrives and easily pulls the others out of the chairs but, once seated, makes less noise. If the chairs were full, the swap leaves the room suddenly silent, and it is that sudden silence that the body feels as withdrawal. If there were already empty chairs, because withdrawal had begun, buprenorphine takes the free space and the body feels relief.

The analogy has limits, like every simplification, but it captures the essential point: precipitated withdrawal depends on how much full agonist is present at the time of the dose. It also prepares the person to understand why the team asks them to wait.

From occupancy to symptom: what the person feels

Precipitated withdrawal resembles spontaneous withdrawal, but it is usually more intense and starts abruptly, soon after the dose. Understanding the origin of each symptom helps to recognize it and explain it.

Symptoms and their physiology

• Sweating, piloerection and mydriasis reflect the autonomic hyperactivity that arises when the opioid brake is suddenly removed.
• Nausea, vomiting, cramping and diarrhea come from the loss of the opioid effect on the gastrointestinal tract.
• Body aches, restlessness and intense anxiety accompany the sharp drop in stimulation in the central nervous system.
• Tachycardia and yawning complete the picture and help to score the scale.

Measure instead of impress

The clinical opioid withdrawal scale, known by the acronym COWS, turns these signs into a reproducible score (Wesson and Ling, 2003). It serves two moments: before the first dose, to confirm that there is enough objective withdrawal, and after it, to notice early if there has been worsening. The cutoff points used to start vary between protocols; follow your service's protocol and record the score.

The difference between "I feel awful" and objective withdrawal

The person may report feeling unwell because of anxiety, fear of withdrawal or expectation of treatment. The report matters and should be welcomed, but the decision to start also relies on objective signs. This distinction does not dismiss the person; it protects them from starting at the wrong moment.

Time deceives: fentanyl and accumulation

Fentanyl changed the reasoning behind buprenorphine initiation. It is highly lipophilic, accumulates in tissues with repeated use and leaves the body more slowly than its short action suggests.

Why the clock fails

An elimination study showed that, in people who use fentanyl frequently, the drug and its metabolites remain detectable for days, longer than expected for a short-acting opioid (Huhn et al., 2020). This means that, even after many hours without use, there may still be enough full agonist for buprenorphine to precipitate withdrawal.

What the clinical data show

In a cohort of hospitalized patients who used fentanyl and started buprenorphine, precipitated withdrawal was uncommon but real, and it was associated with markers of higher fentanyl load and with a higher body mass index (Thakrar et al., 2024). Another study found higher odds of severe withdrawal when buprenorphine was taken shortly after fentanyl, an association that did not appear with methadone (Varshneya et al., 2022). The correct reading of these data is a risk to be stratified, not a rare event that can be ignored.

Other situations where time misleads

Methadone and other long-acting opioids also stay bound for a long time. Anyone transitioning from methadone to buprenorphine faces similar reasoning, with an interval and withdrawal signs that need to be assessed case by case. The ASAM guidance describes these scenarios and the transition precautions (ASAM, National Practice Guideline).

The young man from the opening scene, with different reasoning

Go back to the young man who asked to start treatment. With the physiological reasoning in mind, the first question is no longer "when was the last time?" and becomes "what did you use, how often, and how is your body now?". He says he uses something he believes is heroin, but that in recent months it "is stronger" and lasts less. That sentence is an important clue: in many places, what circulates as heroin contains fentanyl.

The team applies the withdrawal scale and finds a low score. He is anxious, yawning and somewhat uncomfortable, but without mydriasis, without piloerection and without gastrointestinal symptoms. The report of "I feel awful" is real, but the physiology says there is still a lot of agonist occupying receptors.

Instead of refusing to start, the team explains the mechanism in plain language and presents the options: wait at the service with the scale reassessed, come back later with guidance, or discuss a gradual strategy if the service offers one. He chooses to wait. A few hours later, the scale shows clear objective withdrawal, and the first dose is given with reassessment right after. The score falls, and he says for the first time that he feels better.

What changed between the two versions was not the medication or the willingness to treat. It was the reading of the moment. The team swapped the clock for the scale and the history of the substance, and swapped haste for explanation.

Clinical clues for choosing the moment

Choosing the moment means integrating several clues, as in any diagnostic reasoning. None of them, alone, decides.

The clues that weigh most

• Objective withdrawal score measured with a scale, repeated if it is borderline.
• Substance used, with special attention to fentanyl and long-acting opioids.
• Pattern of use: frequency, amount and length of continuous use.
• Time since last use, read in light of the substance.
• The person's account of previous starts and how they went.

Integrate instead of adding up

The post on metacognition in medicine shows how thinking about your own reasoning helps you notice when a single clue is dominating the decision. At the start of buprenorphine, the dominant clue is usually the clock. Ask: "if I removed the information about time, would the other clues tell me this is the moment?".

The pause before the first dose

The diagnostic pause has an equivalent here: a few seconds before the dose to check the scale, the substance and the person's expectation. This pause is short and prevents a good share of precipitated starts.

The error, the starting strategies and the reasoning behind them

Even with good reasoning, precipitated withdrawal can happen. What is done afterwards defines whether the person comes back or gives up.

Recognize it early

An abrupt worsening right after the dose, with intense autonomic and gastrointestinal signs, suggests precipitated withdrawal. Reassessing the scale helps confirm it and track the course.

Treat and keep the connection

In the emergency department case series, the most frequent approach was to give more buprenorphine to occupy the remaining receptors and control the symptoms, along with symptomatic treatment (Spadaro et al., 2023). The reasoning is consistent with the mechanism: if the drop in stimulation comes from swapping a full agonist for a partial one, completing the occupation with the partial agonist tends to stabilize the picture. The exact approach should follow the service protocol and the assessment of whoever is at the patient's side.

Explain what happened

The person needs to know that what they felt has an explanation and is not a sign that the treatment is not for them. A simple sentence helps: "the medication went in at a moment when there was still a lot of the other opioid in your body, and that caused this strong withdrawal; it can be controlled and you can continue".

Learn from the case

A precipitated withdrawal is a great case for team discussion, without looking for blame. The post about morbidity and mortality sessions shows how to turn error into learning. The session question is: which clues were available and how were they weighed? Other useful questions: was the scale applied and recorded? Was the substance asked about specifically, including the possibility of fentanyl? Did the person receive an explanation before the dose? Honest answers to these questions improve the next start more than any new protocol. Reviews of diagnostic error show that synthesis failures, such as giving too much weight to a clue, appear often among the causes of error (Graber et al., 2005).

Start strategies come from the same physiology

There are different start strategies, and each one comes from the same physiology. They change the path, not the logic. Knowing the common mechanism allows you to understand why each strategy makes sense in one scenario and not in another, and to talk with the person about the choice clearly.

Standard start with objective withdrawal

The classic strategy is to wait for sufficient objective withdrawal and then start, with reassessment. A clinical trial in the emergency department showed that starting buprenorphine there, with referral, increased engagement in treatment compared with simple referral (D'Onofrio et al., 2015). The emergency department is, therefore, a legitimate place to begin, as long as the moment is well chosen.

Microdoses

Another strategy uses very small doses of buprenorphine, increased gradually, while the full agonist is still present. The idea, described in the Bern method, is to occupy receptors so slowly that the drop in stimulation never becomes abrupt (Hämmig et al., 2016). The reasoning is the same mechanism, used in your favor.

Guidelines as a starting point

The ASAM practice guideline organizes these approaches and the conditions in which each one makes sense (Kampman and Jarvis, 2015). Use it as a map, not as a substitute for reasoning about the person in front of you.

What to say before the first dose

The conversation before the dose is part of the technique. People who understand the mechanism tolerate the wait better and recognize warning signs earlier. Points worth covering:

• Why waiting for objective withdrawal protects against worse withdrawal.
• That buprenorphine takes the place of the other opioid and, for that reason, the moment matters.
• Which signs indicate that something is not going well soon after the dose.
• What the team will do if the withdrawal worsens.
• How to stay in contact if the person needs to leave before completing the start.

This conversation is also the first step of the bond. The tone matters: explaining as a partner, not as someone imposing a rule, increases the chance that the person comes back if something goes wrong.

Table: clue, mechanism and decision

Clue	Mechanism involved	Implication for the decision
Clear objective withdrawal on the scale	Receptors less occupied by full agonist	More favorable moment to start
Little time since last use	Full agonist still present	Wait, reassess or consider a gradual strategy
Frequent fentanyl use	Accumulation in tissues and slow elimination	Higher risk even with hours without use
Use of methadone or long-acting opioid	Prolonged receptor occupancy	Transition requires careful assessment
Abrupt worsening soon after the dose	Switch from full to partial agonist	Recognize precipitated withdrawal and treat
Report of a difficult previous start	Experience that shapes expectation	Explain the mechanism and agree on warning signs

How NEXO helps train this reasoning

NEXO presents fictional cases with a real clinical presentation and up to six progressive clues. The format trains exactly what starting buprenorphine requires: integrating several clues, noticing when one of them is being given too much weight and revising the hypothesis when new information appears.

The proximity feedback shows how close your guess came to the target diagnosis, which helps separate getting the category right from getting the mechanism right. For those who want to strengthen the basics, the post on how to study physiology, biochemistry and histology suggests ways to connect the basic cycle to the cases. To understand the game, see what NEXO is and the about NEXO page. Usage limits are in Economy.

As a group, NEXO Closer helps discuss cases and compare the weight each person gave to the clues. Those who research, organize content or produce educational material can get to know NEXO Researcher, NEXO Curator and NEXO Creators. All the texts are on the Blog.

A mechanism exercise

After playing a case, pick one symptom and write in two lines the mechanism that explains it. Then ask which clue in the case would change that mechanism. It is the same exercise that lets you predict precipitated withdrawal before it happens.

Frequently asked questions

Why does buprenorphine cause withdrawal if it is also an opioid?

Because it binds more strongly and activates the receptor less than full agonists. When it replaces a full agonist, the stimulation drops suddenly, and the body feels that as withdrawal (Greenwald et al., 2022).

Is it enough to wait a certain number of hours?

Time is an approximation. What weighs most is objective withdrawal measured with a scale, read together with the substance and the pattern of use (Wesson and Ling, 2003).

Does fentanyl change the reasoning?

It does. It accumulates in tissues and leaves slowly, so there may be enough agonist to precipitate withdrawal even after many hours (Huhn et al., 2020).

Is precipitated withdrawal rare?

It is uncommon but real, and more likely with a higher fentanyl load (Thakrar et al., 2024). The right reasoning is to stratify the risk, not to ignore it.

What should be done if it happens?

Recognize it early, treat it according to the service protocol and explain what happened. In the emergency department case series, more buprenorphine was the frequent approach to stabilize (Spadaro et al., 2023).

What are microdoses?

A strategy that occupies receptors gradually with very small doses, to avoid the abrupt drop in stimulation (Hämmig et al., 2016).

Can the person start buprenorphine at home?

In many services, yes, with clear guidance on when to take the first dose, which signs to watch and how to get in touch. The reasoning is the same as in the service: wait for objective withdrawal and reassess. The rules vary by country and by service.

Does this show up on exams?

Partial agonism, affinity and the ceiling effect appear often in pharmacology and in clinical vignettes. The question usually asks you to connect the mechanism to the symptom.

Final checklist

• I measured withdrawal with a scale before the first dose.
• I asked about the substance, the pattern of use and the time since last use.
• I considered fentanyl and long-acting opioids as factors that fool the clock.
• I explained the mechanism and the warning signs to the person before the dose.
• I reassessed the scale after the dose.
• I recognized the abrupt worsening as possible precipitated withdrawal.
• I treated according to the protocol and kept the connection.
• I took the case to a team discussion without looking for someone to blame.

Play the case of the day on NEXO and, for each clue, write the mechanism it suggests before moving to the next one.

References

1. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003. PMID: 12924748
2. Thakrar AP, et al. Buprenorphine-precipitated withdrawal among hospitalized patients using fentanyl. JAMA Netw Open. 2024. PMID: 39331392
3. American Society of Addiction Medicine. National Practice Guideline for the Treatment of Opioid Use Disorder. asam.org
4. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 2015. PMID: 26406300
5. Spadaro A, et al. Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: a case series. J Am Coll Emerg Physicians Open. 2023. PMID: 36704210
6. Varshneya NB, et al. Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. J Addict Med. 2022. PMID: 34816821
7. Huhn AS, et al. Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend. 2020. PMID: 32650192
8. Greenwald MK, et al. A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med. 2022. PMID: 35940992
9. Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014. PMID: 25179217
10. Walsh SL, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994. PMID: 8181201
11. Hämmig R, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016. PMID: 27499655
12. D'Onofrio G, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015. PMID: 25919527
13. Graber ML, Franklin N, Gordon R. Diagnostic error in internal medicine. Arch Intern Med. 2005. PMID: 16009864